Market Intelligence, Clinical Progress, and High-Purity Reagents for Chronic Pain and Neurotrophic Indication Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NGF (Nerve Growth Factor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NGF / beta NGF Recombinant Protein (ECD-Fc / Mutant). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Homodimer Conformation). | View NGF Products |
| Receptor | TrkA (NTRK1) ECD-Fc Fusion Protein. High purity (>95%), HEK293 Expressed. For binding/competition assays. | View NTRK1 Products |
| Co-Receptor | p75NTR (NGFR) ECD Protein. Sequence Verified, Endotoxin Controlled. For ternary complex studies. | View p75NTR Products |
| Gene Delivery | NGF Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View NGF Products |
| Benchmark Ab | Anti-NGF (Sequence of Tanezumab / Fasinumab). Recombinant positive control. Endotoxin <0.1EU/ug. | View NGF Products |
| Validator | NGF siRNA Set. For knockdown verification and assay validation. | View NGF Products |
| Family Control | BDNF Recombinant Protein. Neurotrophin family member for specificity/cross-reactivity testing. | View BDNF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homodimer folding verification (active NGF is non-covalent homodimer) | Non-reducing SEC-HPLC profile provided; Theoretical MW 26 kDa (non-reduced) / 13 kDa (reduced); Mass spec verified |
| Neurotrophin family cross-reactivity screening (BDNF, NT-3, NT-4) | Homolog panel proteins (BDNF, NT-3) strictly verified by mass spec; Sequence identity <50% ensures specific assay design |
| TrkA binding competition (mechanism of action validation) | High-purity TrkA-ECD available (HEK293 expressed, native glycosylation); SPR-ready format |
| Cross-species preclinical evaluation (Human/Cyno/Mouse/Rat) | Ortholog proteins available with >95% purity; Sequence alignment >90% for translational studies |
| False positives in neurite outgrowth assays | Validated siRNA included for specificity checks; Neutralizing antibody controls available |
Live NGF / beta NGF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NGF therapeutics is highly dynamic, historically characterized by potent monoclonal antibodies aimed at chronic pain conditions like osteoarthritis and lower back pain. While systemic anti-NGF mAbs have faced stringent safety scrutiny regarding joint-related side effects (e.g., rapidly progressive osteoarthritis), the focus is shifting toward localized delivery mechanisms, bispecific modalities, and alternative indications such as neurotrophic keratitis (where recombinant NGF is approved). As first-generation therapies navigate the regulatory clinic, the next wave of R&D is targeting localized target engagement and dual-pathway inhibition to mitigate safety risks. Key players include Pfizer, Lilly, Regeneron, and Dompé.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Anti-NGF) | Pfizer, Lilly, Regeneron, J&J | Osteoarthritis, Chronic Low Back Pain | TrkA competition assay (Need high-purity NGF & TrkA-ECD) |
| Recombinant Protein | Dompé | Neurotrophic Keratitis | Stability/Formulation Assay (Need strict Endotoxin control) |
| TrkA Inhibitor (Small Molecule) | Eisai, Daewoong | Neuropathic Pain, Cancer Pain | Selectivity Assay (Need Mutant vs WT TrkA Proteins) |
| Bispecific (NGF/TrkA) | Various Biotechs | Inflammatory Pain, Neurodegeneration (AD) | Heterodimer Validation (Need Cross-reactive Abs & dual antigens) |
| Gene Therapy (NGF delivery) | NGN Biotech | Alzheimer's, Corneal Neurotrophic Keratitis | Overexpression validation (Need Lentivirus & siRNA controls) |
Molecular Differentiation & Assay Strategy
To develop best-in-class NGF therapeutics, the following molecular properties must be addressed:
- Affinity & Potency: Requires pM-level affinity to fully block NGF-TrkA interaction while maintaining balanced binding kinetics. Assay: SPR/BLI using high-purity TrkA-ECD.
- Neurotrophin Selectivity: Must avoid cross-reactivity with BDNF, NT-3, NT-4 to prevent CNS side effects. Assay: Cross-reactivity panel using BDNF, NT-3 homolog proteins.
- Cross-species Reactivity: Preclinical studies require mouse, rat, and cynomolgus models. Assay: Multi-species ortholog proteins (Human/Cyno/Mouse/Rat) for ELISA/FACS.
- Epitope Binning: Distinguish between TrkA-binding site blockers (Class 1) and non-blockers (Class 2). Assay: Competition binding assay using NGF and TrkA-ECD.
- Functional Validation: Neurite outgrowth inhibition in PC12 cells or primary neurons. Assay: Lentivirus overexpression system with siRNA controls.
TarMart Advantage: High-purity HEK293-expressed NGF with native homodimer conformation, strict endotoxin control (<1 EU/ug), and clinical benchmark antibodies (Tanezumab biosimilar) for assay standardization.